Jingkun Qu1, Xixi Zhao2, Jizhao Wang1, Xu Liu1, Yan Yan1, Lin Liu1, Hui Cai1,3, Hangying Qu4, Ning Lu4, Yuchen Sun5, Feidi Wang2, Jiansheng Wang1, Jia Zhang1. 1. The Second Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China. 2. Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China. 3. Department of Vascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China. 4. Department of Oncological Surgery, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, P.R. China. 5. Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Abstract
BACKGROUND: Proto-oncogene MYC has been indicated to promote progression of many cancers. However, prognostic and clinicopathological significance of MYC in breast cancer need further evaluation. METHODS: We searched EMBASE and PubMed databases to find useful studies. We analyzed relationships between high MYC expression and prognostic data/ clinicopathological features through hazard ratio (HR) and odds ratio (OR). Each statistical test was two-sided. RESULTS: There were 29 studies (36 cohorts) with 12621 patients enrolled in our study The MYC overexpression was associated with worse DFS/RFS (disease/relapse free survival) in 11 studies (16 cohorts) with 5390 patients, and OS (overall survival) of 7 studies (8 cohorts) with 2672 patients. Subgroup analysis according to ethnicity/technique/data source displayed that MYC overexpression was associated with poor DFS/RFS in FISH, other technique, all data source and Asian/Non-Asian subgroup, and worse OS in all subgroups. In addition, MYC overexpression was related to large tumor size, high histologic grade, lymph node metastasis, negative hormone receptors and positive Ki67 expression. CONCLUSIONS: Our results showed that MYC overexpression was associated with worse prognosis and high risk of breast cancer, especially in patients with negative hormone receptors, which highlighted the potential of MYC as a significant prognostic biomarker of breast cancer.
BACKGROUND: Proto-oncogene MYC has been indicated to promote progression of many cancers. However, prognostic and clinicopathological significance of MYC in breast cancer need further evaluation. METHODS: We searched EMBASE and PubMed databases to find useful studies. We analyzed relationships between high MYC expression and prognostic data/ clinicopathological features through hazard ratio (HR) and odds ratio (OR). Each statistical test was two-sided. RESULTS: There were 29 studies (36 cohorts) with 12621 patients enrolled in our study The MYC overexpression was associated with worse DFS/RFS (disease/relapse free survival) in 11 studies (16 cohorts) with 5390 patients, and OS (overall survival) of 7 studies (8 cohorts) with 2672 patients. Subgroup analysis according to ethnicity/technique/data source displayed that MYC overexpression was associated with poor DFS/RFS in FISH, other technique, all data source and Asian/Non-Asian subgroup, and worse OS in all subgroups. In addition, MYC overexpression was related to large tumor size, high histologic grade, lymph node metastasis, negative hormone receptors and positive Ki67 expression. CONCLUSIONS: Our results showed that MYC overexpression was associated with worse prognosis and high risk of breast cancer, especially in patients with negative hormone receptors, which highlighted the potential of MYC as a significant prognostic biomarker of breast cancer.
Entities:
Keywords:
MYC; breast cancer; clinicopathology; meta-analysis; prognosis
Authors: Erik S Knudsen; A Kathleen McClendon; Jorge Franco; Adam Ertel; Paolo Fortina; Agnieszka K Witkiewicz Journal: Cell Cycle Date: 2015 Impact factor: 4.534
Authors: Magdalena A Cichon; Megan E Moruzzi; Tiziana A Shqau; Erin Miller; Christine Mehner; Stephen P Ethier; John A Copland; Evette S Radisky; Derek C Radisky Journal: Cancer Res Date: 2016-04-13 Impact factor: 12.701
Authors: David S P Tan; Caterina Marchió; Robin L Jones; Kay Savage; Ian E Smith; Mitch Dowsett; Jorge S Reis-Filho Journal: Breast Cancer Res Treat Date: 2007-10-06 Impact factor: 4.872
Authors: Alison J Butt; C Marcelo Sergio; Claire K Inman; Luke R Anderson; Catriona M McNeil; Amanda J Russell; Marco Nousch; Thomas Preiss; Andrew V Biankin; Robert L Sutherland; Elizabeth A Musgrove Journal: Breast Cancer Res Date: 2008-03-29 Impact factor: 6.466
Authors: Toshiaki Iwase; Kenichi Harano; Hiroko Masuda; Kumiko Kida; Kenneth R Hess; Ying Wang; Luc Dirix; Steven J Van Laere; Anthony Lucci; Savitri Krishnamurthy; Wendy A Woodward; Rachel M Layman; François Bertucci; Naoto T Ueno Journal: BMC Cancer Date: 2020-05-18 Impact factor: 4.430
Authors: Say Li Kong; Xingliang Liu; Swee Jin Tan; Joyce A Tai; Ler Yee Phua; Huay Mei Poh; Trifanny Yeo; Yong Wei Chua; Yu Xuan Haw; Wen Huan Ling; Raymond Chee Hui Ng; Tira J Tan; Kiley Wei Jen Loh; Daniel Shao-Weng Tan; Quan Sing Ng; Mei Kim Ang; Chee Keong Toh; Yi Fang Lee; Chwee Teck Lim; Tony Kiat Hon Lim; Axel M Hillmer; Yoon Sim Yap; Wan-Teck Lim Journal: Front Oncol Date: 2021-07-16 Impact factor: 6.244